Exciting news for people living with idiopathic pulmonary fibrosis (IPF). Two large clinical trials TETON-1 and TETON-2 showed that an inhaled medication called treprostinil (Tyvaso) slows the loss of lung function in patient with … [Read more...]
Nerandomilast in Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis: A Promising New Therapeutic Approach
Introduction Idiopathic Pulmonary Fibrosis (IPF) is a progressive and often fatal interstitial lung disease marked by chronic fibrosis and inflammation of lung tissue. IPF remains a significant therapeutic challenge despite the availability of antifibrotic agents like pirfenidone and nintedanib. Recent attention has turned toward inflammation-modulating and immunoregulatory … [Read more...]
Pamrevlumab Ineffective in Treating IPF
In June of 2023 Fibrogen announced the results of the ZEPHYRUS-1 clinical trial of Pamrevlumab in IPF. Pamrevlumab entered phase 3 with much anticipation. Phase 2 work suggested that the molecule had a high chance of success. Unfortunately, in the phase 3 study which included 356 subjects, Pamrevlumab was not effective at preserving lung function. As a result, Fibrogen … [Read more...]
Inhaled Nitric Oxide and Pulmonary Fibrosis
Bellerophon Phase 2 Study In November, Bellerophon announced that their phase 2 study of portable inhaled nitric oxide for pulmonary fibrosis led to clinically important improvements for patients. This is great news for the pulmonary fibrosis community. Patients with many different types of pulmonary fibrosis were included in the study. All had to be using … [Read more...]